Immunotherapy for Advanced Rare Cancers

Recruiting in Palo Alto (17 mi)

+16 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Canadian Cancer Trials Group

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.

Eligibility Criteria

This trial is for patients with advanced rare tumors who have measurable disease, are over 16 years old (or over 5 for a specific cohort), and have an ECOG performance status of 0-2. They should not have received certain prior treatments and must meet lab requirements. Exclusions include cardiovascular issues, recent heart or brain events, inability to absorb oral meds, known drug sensitivities, other cancer histories or concurrent cancer treatments.

Inclusion Criteria

I am at least 16 years old, or at least 5 for a specific study group.

Laboratory requirements met (hematology, chemistry)

You are expected to live for at least 12 more weeks.

+10 more

Exclusion Criteria

I have had cancer before, but it was a specific type that is allowed.

You are pregnant or breastfeeding.

You are allergic to the study drug or any of its ingredients.

+5 more

Participant Groups

The study tests Sunitinib and Temsirolimus in patients with no cure-available cancers to see if these drugs can shrink the tumors. It's a Phase II trial which means it's checking the effectiveness of these drugs on this particular type of tumor after initial safety has been established.

2Treatment groups

Active Control

Group I: SunitinibActive Control1 Intervention

Group II: TemsirolimusActive Control1 Intervention

Sunitinib is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸 Approved in United States as Sutent for: